StockNews.com Initiates Coverage on NovaBay Pharmaceuticals (NYSE:NBY)

StockNews.com started coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY – Get Rating) in a research report released on Saturday. The firm issued a hold rating on the stock.

NovaBay Pharmaceuticals Stock Performance

NBY stock traded down $0.08 during trading on Friday, reaching $1.50. The stock had a trading volume of 18,810 shares, compared to its average volume of 13,219. The firm has a fifty day moving average price of $2.15 and a 200 day moving average price of $1.19. NovaBay Pharmaceuticals has a 1-year low of $1.24 and a 1-year high of $12.64.

NovaBay Pharmaceuticals Company Profile

(Get Rating)

NovaBay Pharmaceuticals, Inc engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase, CelleRx, and DERMAdoctor. The company was founded by Ramin Najafi on January 19, 2000 and is headquartered in Emeryville, CA.